We advise the trade body for generic medicines suppliers, who account for 4 in 5 of all NHS medicines. Throughout the Covid-19 pandemic, we have worked extremely closely with Government and NHS to ensure that the industry met the unprecedent demand for critical care medicines. We developed policy solutions to keep supplies flowing and to plan for subsequent waves.